Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
INTRODUCTION:Hemophilia B is an inherited X chromosome-linked disorder characterized by impaired blood clotting owing to the absence of functional coagulation factor IX. Due to the relatively short half-life of factor IX, patients with hemophilia B require frequent factor IX infusions to maintain pr...
Main Authors: | Garabet G Toby, Tongyao Liu, Yang Buyue, Xin Zhang, Alan J Bitonti, Glenn F Pierce, Jurg M Sommer, Haiyan Jiang, Robert T Peters |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4740463?pdf=render |
Similar Items
-
A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.
by: Yang Buyue, et al.
Published: (2014-01-01) -
Treatment of hemophilia B: focus on recombinant factor IX
by: Franchini M, et al.
Published: (2013-02-01) -
Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
by: Mancuso ME, et al.
Published: (2014-03-01) -
GlycoPEGylated recombinant factor IX for hemophilia B in context
by: Santagostino E, et al.
Published: (2018-09-01) -
Leishmania amazonensis exhibits phosphatidylserine-dependent procoagulant activity, a process that is counteracted by sandfly saliva
by: Natalia Cadaxo Rochael, et al.
Published: (2013-09-01)